FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377020104> ?p ?o ?g. }

• W4377020104 endingPage "1072.e4" @default.
• W4377020104 startingPage "1061" @default.
• W4377020104 abstract "Checkpoint inhibitors are effective in recurrent/metastatic nasopharyngeal cancer (R/M NPC). RATIONALE-309 (NCT03924986) randomized 263 treatment-naive R/M NPC patients to tislelizumab or placebo every 3 weeks (Q3W), plus chemotherapy (Q3W for 4-6 cycles). At interim analysis, progression-free survival (PFS) was significantly longer with tislelizumab-chemotherapy versus placebo-chemotherapy (hazard ratio: 0.52; 95% confidence interval: 0.38, 0.73; p < 0.0001). PFS benefit for tislelizumab-chemotherapy versus placebo-chemotherapy was observed regardless of programmed death-ligand 1 expression. PFS after next line of treatment and overall survival showed favorable trends for tislelizumab-chemotherapy versus placebo-chemotherapy. The safety profile was similar between arms. Gene expression profiling (GEP) identified immunologically hot tumors, and showed an activated dendritic cell (DC) signature was associated with tislelizumab-chemotherapy PFS benefit. Our results support that tislelizumab-chemotherapy should be considered as first-line treatment for R/M NPC, and GEP and activated DC signature results may help identify patients who might benefit most from immunochemotherapy treatment. VIDEO ABSTRACT." @default.
• W4377020104 created "2023-05-19" @default.
• W4377020104 creator A5010748983 @default.
• W4377020104 creator A5014860164 @default.
• W4377020104 creator A5016412981 @default.
• W4377020104 creator A5020252828 @default.
• W4377020104 creator A5020497057 @default.
• W4377020104 creator A5023899283 @default.
• W4377020104 creator A5024689200 @default.
• W4377020104 creator A5025738678 @default.
• W4377020104 creator A5026009881 @default.
• W4377020104 creator A5028090912 @default.
• W4377020104 creator A5028566264 @default.
• W4377020104 creator A5032868375 @default.
• W4377020104 creator A5044447392 @default.
• W4377020104 creator A5046131158 @default.
• W4377020104 creator A5047191423 @default.
• W4377020104 creator A5060470951 @default.
• W4377020104 creator A5062949245 @default.
• W4377020104 creator A5066716873 @default.
• W4377020104 creator A5067139205 @default.
• W4377020104 creator A5067242485 @default.
• W4377020104 creator A5069224733 @default.
• W4377020104 creator A5074626715 @default.
• W4377020104 creator A5079423095 @default.
• W4377020104 creator A5080476123 @default.
• W4377020104 creator A5083283370 @default.
• W4377020104 creator A5085159332 @default.
• W4377020104 creator A5086758549 @default.
• W4377020104 creator A5089211608 @default.
• W4377020104 creator A5090366405 @default.
• W4377020104 creator A5091972374 @default.
• W4377020104 date "2023-06-01" @default.
• W4377020104 modified "2023-10-16" @default.
• W4377020104 title "Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)" @default.
• W4377020104 cites W2060499368 @default.
• W4377020104 cites W2403421660 @default.
• W4377020104 cites W2512237822 @default.
• W4377020104 cites W2747272999 @default.
• W4377020104 cites W2752300866 @default.
• W4377020104 cites W2803757775 @default.
• W4377020104 cites W2890100090 @default.
• W4377020104 cites W2935893184 @default.
• W4377020104 cites W3031475478 @default.
• W4377020104 cites W3036157555 @default.
• W4377020104 cites W3092442011 @default.
• W4377020104 cites W3115988948 @default.
• W4377020104 cites W3124559501 @default.
• W4377020104 cites W3144903047 @default.
• W4377020104 cites W3162215872 @default.
• W4377020104 cites W3164926090 @default.
• W4377020104 cites W3177205810 @default.
• W4377020104 cites W3189017418 @default.
• W4377020104 cites W3190270536 @default.
• W4377020104 cites W3204336527 @default.
• W4377020104 cites W4205225889 @default.
• W4377020104 cites W4205496349 @default.
• W4377020104 cites W4213128573 @default.
• W4377020104 cites W4281805752 @default.
• W4377020104 doi "https://doi.org/10.1016/j.ccell.2023.04.014" @default.
• W4377020104 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37207654" @default.
• W4377020104 hasPublicationYear "2023" @default.
• W4377020104 type Work @default.
• W4377020104 citedByCount "10" @default.
• W4377020104 countsByYear W43770201042023 @default.
• W4377020104 crossrefType "journal-article" @default.
• W4377020104 hasAuthorship W4377020104A5010748983 @default.
• W4377020104 hasAuthorship W4377020104A5014860164 @default.
• W4377020104 hasAuthorship W4377020104A5016412981 @default.
• W4377020104 hasAuthorship W4377020104A5020252828 @default.
• W4377020104 hasAuthorship W4377020104A5020497057 @default.
• W4377020104 hasAuthorship W4377020104A5023899283 @default.
• W4377020104 hasAuthorship W4377020104A5024689200 @default.
• W4377020104 hasAuthorship W4377020104A5025738678 @default.
• W4377020104 hasAuthorship W4377020104A5026009881 @default.
• W4377020104 hasAuthorship W4377020104A5028090912 @default.
• W4377020104 hasAuthorship W4377020104A5028566264 @default.
• W4377020104 hasAuthorship W4377020104A5032868375 @default.
• W4377020104 hasAuthorship W4377020104A5044447392 @default.
• W4377020104 hasAuthorship W4377020104A5046131158 @default.
• W4377020104 hasAuthorship W4377020104A5047191423 @default.
• W4377020104 hasAuthorship W4377020104A5060470951 @default.
• W4377020104 hasAuthorship W4377020104A5062949245 @default.
• W4377020104 hasAuthorship W4377020104A5066716873 @default.
• W4377020104 hasAuthorship W4377020104A5067139205 @default.
• W4377020104 hasAuthorship W4377020104A5067242485 @default.
• W4377020104 hasAuthorship W4377020104A5069224733 @default.
• W4377020104 hasAuthorship W4377020104A5074626715 @default.
• W4377020104 hasAuthorship W4377020104A5079423095 @default.
• W4377020104 hasAuthorship W4377020104A5080476123 @default.
• W4377020104 hasAuthorship W4377020104A5083283370 @default.
• W4377020104 hasAuthorship W4377020104A5085159332 @default.
• W4377020104 hasAuthorship W4377020104A5086758549 @default.
• W4377020104 hasAuthorship W4377020104A5089211608 @default.
• W4377020104 hasAuthorship W4377020104A5090366405 @default.
• W4377020104 hasAuthorship W4377020104A5091972374 @default.
• W4377020104 hasBestOaLocation W43770201041 @default.
• W4377020104 hasConcept C126322002 @default.

• next